PharmaTher Provides Complete Response Amendment for US FDA New Drug Application for Ketamine
Portfolio Pulse from
PharmaTher Holdings Ltd. has resubmitted a complete response amendment to the FDA for its new drug application for Ketamine, addressing minor deficiencies. The company expects FDA approval by Q2-2025, which could solve the Ketamine shortage and unlock its pharmaceutical potential.
March 03, 2025 | 1:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
PharmaTher has resubmitted its FDA application for Ketamine, addressing minor deficiencies. Approval is expected by Q2-2025, which could solve the Ketamine shortage and enhance its pharmaceutical use.
The resubmission of the FDA application for Ketamine by PharmaTher addresses minor deficiencies, indicating a high likelihood of approval by Q2-2025. This could positively impact the stock as it addresses a Ketamine shortage and enhances its pharmaceutical potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100